CD274 and melanoma: Monoclonal antibodies inhibiting specific ICIs, including anti-programmed cell death protein 1 (PD-1), anti-programmed death ligand-1 (PDL-1), and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), alone or in combination, have been tested with great success in clinical trials and approved by the FDA for the treatment of advanced melanoma [47,48].